LIVE WEBINAR: Saturday, March 20, 2021, 3:00 PM – 4:00 PM Central Time (4:00 PM – 5:00 PM Eastern Time)

Cases from the Community: Investigators Discuss the Role of PARP Inhibition in the Care of Actual Patients with Ovarian Cancer

A CME/MOC Virtual Satellite Symposium in Conjunction with the Society of Gynecologic Oncology’s 2021 Virtual Annual Meeting on Women’s Cancer

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Saturday, March 20th for this CME/MOC-accredited webinar
3:00 PM – 4:00 PM CT (4:00 PM – 5:00 PM ET)

Faculty

Susana Banerjee, MBBS, MA, PhD
Consultant Medical Oncologist
Research Lead, Gynecological Cancers
The Royal Marsden NHS Foundation Trust
Reader in Women’s Cancers
The Institute of Cancer Research
The Royal Marsden NHS Foundation Trust
London, United Kingdom

Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts



Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

Saturday, March 20, 2021
3:00 PM – 4:00 PM Central Time (4:00 PM – 5:00 PM Eastern Time)
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • Genetic testing in ovarian cancer (OC); integration of PARP inhibitor maintenance therapy into the management of newly diagnosed OC with a BRCA mutation
  • Clinical utility of maintenance PARP inhibitors for patients with BRCA wild-type advanced OC
  • Available data with PARP inhibitors in combination with immunotherapeutic and chemotherapeutic agents in the management of advanced OC
  • Identification and management of side effects and other practical considerations with the use of PARP inhibitors for advanced OC

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in ovarian cancer (OC), and use the results of these assessments to guide long-term treatment.
  • Recognize the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and appropriately integrate this agent into clinical care.
  • Review emerging trial data evaluating niraparib as maintenance therapy in the first-line setting for patients with or without BRCA mutations, and consider the clinical and research implications of these findings.
  • Understand the biologic rationale for and available data with the use of PARP inhibitors in combination with anti-angiogenic agents, and discern how this strategy affects current therapeutic algorithms.
  • Appreciate available clinical trial data with PARP inhibitors in combination with front-line chemotherapy and then as maintenance treatment for patients with newly diagnosed OC, and evaluate the potential role of this novel therapeutic approach.
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiple regimen-refractory OC in order to personalize care plans incorporating these agents.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
  • Develop an understanding of the rationale for, emerging data with and potential clinical roles of combining PARP inhibitors with anti-PD-1/PD-L1 antibodies, and counsel appropriate patients about the availability of and participation in research studies.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.